Clinical effects of the 5-HT1A partial agonists in depression: A composite analysis of buspirone in the treatment of depression

Journal of Clinical Psychopharmacology

Volumn 10, Issue 3, 1990, Pages 67S-76S

  Robinson, Donald S ^a   Rickels, Karl ^b   Feighner, John ^c   Fabre, Louis F ^d   Gammans, Richard E ^d   Shrotriya, Rajesh C ^a   Alms, Donald R ^a   Andary, Joseph J ^a   Messina, Marianne E ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c Feighner Research Institute   (United States)

^d Research Testing Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; GEPIRONE; PLACEBO; SEROTONIN 1A RECEPTOR;

ADULT; AGED; ANXIETY; CONFERENCE PAPER; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT;

ADOLESCENT; ADULT; AGED; BIPOLAR DISORDER; BUSPIRONE; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMAN; MALE; MIDDLE AGE; MULTICENTER STUDIES; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, SEROTONIN;

EID: 0025376085     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Tompkins EC, Clemento AJ, Taylor DP, et al. Inhibition of aggessive behavior in rhesus monkeys by buspirone. Res Commun Psychol Psychiatry Behav 1980;5:337–52.
2. DeVivo M, Maayani S. Characterization of the 5-hydroxytrypt-amine-lA receptor-mediated inhibition of forskolin-stimulated adenylate cyclase activity in guinea pig and rat hippocampal membranes J Pharmacol Exn Ther 1986;238:248–53.
3. Peroutka SJ. 5-Hydroxytryptamine receptor subtypes: molecular, biochemical and physiological characterization. Trends Neurosci 1988;11:496–500.
4. Sherman AD, Sacquitne JL, Petty F. Specificity of the learned helplessness model of depression. Pharmacol Biochem Behav 1982;16:449–54.
5. Cervo L, Grignaschi G, Samanin R. Different effects of intracerebral and systemic administration of buspirone in the forced swimming test: involvement of a metabolite. Life Sci 1988;43:2095–102.
6. Taylor DP. Buspirone, a new approach to treatment of anxiety. FASEB J 1988;2:2445–52.
7. Kennett GA, Dourish CT, Curzon G. Antidepressant-like action of agonists and conventional antidepressants in an animal model of depression. Eur J Pharmacol 1987;134:265–74.
8. Rickels K, Weisman K, Norstad N, et al. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 1982;43:81–6.
9. Pecknold JC, Familamira P, Chang H, et al. Buspirone: anxiolytic? Prog Neuronsvchonharmacol Biol Psychiatry 1985;9:639–46.
10. Böhm C, Ganlnlans R, Alms D, et al. A double-blind comparison of buspirone, clobazam and placebo in patients with anxiety treated in a general practice setting. J Clin Psychopharmacol 1990; 10(suppl):38–42S.
11. Diagnostic and statistical manual of mental disorders, 3rd ed. Washington, DC: American Psychiatric Association 1980.
12. Data on file, Bristol-Myers Squibb Co., Wallingford, CT.
13. Feighner JP, Meridith CH, Hendrickson GA. A double-blind comparison of buspirone and diazepam in outpatients with generalized anxiety disorder. J Clin Psychiatry 1982;43:103–7.
14. Goldberg HL, Finnerty RJ. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am J Psychiatry 1979;136:1184–7
15. Schweizer EE, Amsterdam J, Rickels K, et al. Open trial of buspirone in the treatment of major depressive disorder. Psychopharmacol Bull 1986;22:183–5.
16. Diagnostic and statistical manual of mental disorders, 3rd ed, rev. Washington, DC: American Psychiatric Association, 1987.
17. Robinson DS, Roberts DL, Copp JE, et al. Diagnostic and clinical assessment issues in the development and therapeutic evaluation of psychopharmacologic agents. Psychopharmacol Bull 1989;25:9–15.
18. Wise CD, Berger BD, Stein L. Benzodiazepine: anxiety-reducing activity by reduction of serotonin turnover in the brain. Science 1972;177:180–3.
19. Tye NC, Iversen SD, Green AR. The effects of benzodiazepines and serotonergic manipulations on punished responding. Neuropharmacology 1979;18:689–96
20. Riblet LA, Taylor DP, Eison MS, et al. Pharmacology and neurochemistry of buspirone. J Clin Psychiatry 1982;43:11–5.
21. 1A receptors. Biol Psychiatry 1985;20:971–9.
22. VanderMaelen CP, Matheson KG, Wilderman RC, et al. Inhibition of serotonergic dorsal raphe neurons by systemic and iontophoretic administration of buspirone, a non-benzodiazepine anxiolytic drug. Eur J Pharmacol 1986;129:123–30.
23. Cott JM, Kurtz NM, Robinson DS, et al. A 5-HT ligand with both antidepressant and anxiolytic properties. Psychopharmacol Bull 1988;24:164–7.
24. Jenkins SW, Robinson DS, Fabre LF Jr, Andary JJ, Messina ME, Reich LA. Gepirone in the treatment of major depression. J Clin Psychopharmacol 1990;10(suppl):77–85S.